Suppr超能文献

过氧化物酶体增殖物激活受体α在动脉粥样硬化中的作用。

Role of peroxisome proliferator-activated receptor α in atherosclerosis.

作者信息

Cao Heng, Wen Gao, Li Hongli

机构信息

Department of Cardiology, Shanghai First People's Hospital, College of Medicine, Shanghai Jiaotong University, Shanghai 200080, P.R. China.

出版信息

Mol Med Rep. 2014 May;9(5):1755-60. doi: 10.3892/mmr.2014.2020. Epub 2014 Mar 6.

Abstract

Atherosclerosis is an inflammatory disease involving the immune response. In addition to lowering the cholesterol level, the peroxisome proliferator-activated receptor α (PPAR-α) can prevent atherosclerosis via its pleiotropic anti-inflammatory effects. However, the role of PPAR-α in modulating inflammatory progression of atherosclerosis has rarely been studied. Thus, we aimed to investigate the role of PPAR-α in atherosclerosis by evaluating the expression of inflammatory cytokines induced by PPAR-α in an in vivo rabbit model. New Zealand White rabbits were randomly divided into 5 groups: control, high-fat diet + balloon injury, high-fat diet + balloon injury + placebo, high-fat diet + balloon injury + fenofibrate, and high-fat diet + balloon injury + WY-14643. The femoral arteries of rabbits were balloon-injured after initiation of the high-fat diet and before administration of fenofibrate, WY-14643 or placebo solution. Atherosclerosis was induced by high-fat diet and balloon angioplasty, and the vessel wall lumen occlusion was determined by measuring the stenosis rate. PPAR-α gene expression was examined by quantitative polymerase chain reaction analysis. The cellular localization and distribution of PPAR-α was observed by immunohistochemistry, and its protein level was assessed by western blot analysis. The production of interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and P-selectin, which are major inflammatory factors involved in atherosclerosis, was monitored by an enzyme-linked immunosorbent assay (ELISA). Treatment with PPAR-α agonists (fenofibrate or WY-14643) reduced the vascular occlusion rate, as compared to the high-fat diet + balloon injury and the placebo groups. Furthermore, the expression of PPAR-α at both the protein and the mRNA level was increased in the fenofibrate and WY-14643 groups. According to the results, the TNF-α and P-selectin levels were reduced in the fenofibrate and WY-14643 groups. These results suggest that PPAR-α activation can attenuate the effects of atherosclerosis by inhibiting the expression of major inflammatory factors in a rabbit atherosclerosis model.

摘要

动脉粥样硬化是一种涉及免疫反应的炎症性疾病。过氧化物酶体增殖物激活受体α(PPAR-α)除了能降低胆固醇水平外,还可通过其多效性抗炎作用预防动脉粥样硬化。然而,PPAR-α在调节动脉粥样硬化炎症进展中的作用鲜有研究。因此,我们旨在通过评估PPAR-α在体内兔模型中诱导的炎症细胞因子表达,来研究PPAR-α在动脉粥样硬化中的作用。将新西兰白兔随机分为5组:对照组、高脂饮食+球囊损伤组、高脂饮食+球囊损伤+安慰剂组、高脂饮食+球囊损伤+非诺贝特组以及高脂饮食+球囊损伤+WY-14643组。在开始高脂饮食后且在给予非诺贝特、WY-14643或安慰剂溶液之前,对兔的股动脉进行球囊损伤。通过高脂饮食和球囊血管成形术诱导动脉粥样硬化,并通过测量狭窄率来确定血管壁管腔闭塞情况。通过定量聚合酶链反应分析检测PPAR-α基因表达。通过免疫组织化学观察PPAR-α的细胞定位和分布,并通过蛋白质印迹分析评估其蛋白水平。通过酶联免疫吸附测定(ELISA)监测白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)和P-选择素的产生,这些是参与动脉粥样硬化的主要炎症因子。与高脂饮食+球囊损伤组和安慰剂组相比,用PPAR-α激动剂(非诺贝特或WY-14643)治疗可降低血管闭塞率。此外,非诺贝特组和WY-14643组中PPAR-α在蛋白和mRNA水平的表达均增加。根据结果,非诺贝特组和WY-14643组中的TNF-α和P-选择素水平降低。这些结果表明,在兔动脉粥样硬化模型中,激活PPAR-α可通过抑制主要炎症因子的表达来减轻动脉粥样硬化的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验